Sponsor: Amgen, Inc.
Sponsor Study ID: 20200439
Study Title: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)
CTO #: 103430
NCT Number: NCT04885998
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of AMG 757 in combination with AMG 404.